Becton Dickinson Ranks 75th in Turnover as $17.5 Billion Merger with Waters Corp Aims for $9 Billion in Revenues by 2030

On July 15, 2025, Becton Dickinson (BDX) closed the trading day with a turnover of $10.67 billion, ranking 75th in the day's stock market turnover. The stock price increased by 0.69%, marking the second consecutive day of gains, with a total increase of 1.33% over the past two days.

Becton Dickinson's biosciences and diagnostic-solutions business is set to merge with Waters Corp. in a deal valued at $17.5 billion. This strategic move aims to create a diagnostics powerhouse targeting $9 billion in revenues by 2030. The transaction, structured as a tax-efficient Reverse Morris Trust, is expected to significantly expand Waters' market reach and enhance its capabilities in regulated, high-volume testing.

The merger is anticipated to close in the first quarter of 2026, with Barclays serving as the financial adviser to Waters and Citi acting as the lead financial adviser to Becton Dickinson. This deal is seen as a strategic fit, combining the strengths of both companies to create a leading player in the life science and diagnostics sector.